Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia.

Wojciech Jurczak,Nagah Elmusharaf,Christopher P Fox,William Townsend,Amanda G Paulovich,Jeffrey R Whiteaker,Fanny Krantz,Chuan-Chuan Wun,Graeme Parr,Shringi Sharma,Veerendra Munugalavadla,Richa Manwani,Emma Dean,Talha Munir

Therapeutic advances in hematology（2023）

Cited 0|Views33
No score
Abstract
NCT03328273.
More
Translated text
Key words
relapsed/refractory chronic lymphocytic leukemia,ceralasertib,acalabrutinib,monotherapy,high-risk
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined